NCT02964039

Brief Summary

The purpose of this study is to determine whether a novel treadmill training intervention can improve the gait stabilization strategy used by individuals who have experienced a stroke.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
54

participants targeted

Target at P50-P75 for not_applicable stroke

Timeline
Completed

Started Apr 2017

Typical duration for not_applicable stroke

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 4, 2016

Completed
11 days until next milestone

First Posted

Study publicly available on registry

November 15, 2016

Completed
5 months until next milestone

Study Start

First participant enrolled

April 1, 2017

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 31, 2020

Completed
1.3 years until next milestone

Results Posted

Study results publicly available

July 28, 2021

Completed
Last Updated

June 3, 2024

Status Verified

December 1, 2023

Enrollment Period

3 years

First QC Date

November 4, 2016

Results QC Date

July 6, 2021

Last Update Submit

December 19, 2023

Conditions

Keywords

strokerehabilitationgait

Outcome Measures

Primary Outcomes (1)

  • Partial Correlation Between Pelvis Displacement and Paretic Step Width During Gait (Change From Baseline)

    A custom measure that quantifies the strength of the relationship between body mechanics and foot placement. This measure falls within a relatively narrow range among neurologically intact controls, but is substantially reduced in some individuals who have experienced a stroke, indicating a reduced ability to stabilize their gait pattern. This measure relates the mechanical state of the body at the start of each step (mediolateral pelvis displacement and velocity of the pelvis relative to the stance foot) to the step width at the end of the step. Specifically, the partial linear correlation between pelvis displacement and step width was calculated, accounting for variation in pelvis velocity. The change in this measure relative to baseline is calculated at four time points (after 4, 8, 12, and 24 weeks).

    baseline, 4-weeks, 8-weeks, 12-weeks, 24-weeks

Secondary Outcomes (5)

  • Functional Gait Assessment (Change From Baseline)

    baseline, 4-weeks, 8-weeks, 12-weeks, 24-weeks

  • Activities-specific Balance Confidence Scale (Change From Baseline)

    baseline, 4-weeks, 8-weeks, 12-weeks, 24-weeks

  • 10-meter Walk Test (Change From Baseline)

    baseline, 4-weeks, 8-weeks, 12-weeks, 24-weeks

  • Fall Incidence

    6 months (during 12 week follow-up period)

  • Fear of Falling

    6 months (at completion of 12-week Follow-up period)

Study Arms (3)

Error reduction

EXPERIMENTAL

Participants will complete a 12-week training program, in which they practice walking on a treadmill for 30-minutes during twice-weekly training sessions. During these sessions, participants will interface with a custom-built force-field able to exert mediolateral forces on the legs, which will be in "error reduction" mode. This training period will be followed by a 12-week follow-up period. Five assessment sessions will be interspersed throughout this total 24-week period.

Behavioral: Error reduction

Error augmentation

EXPERIMENTAL

Participants will complete a 12-week training program, in which they practice walking on a treadmill for 30-minutes during twice-weekly training sessions. During these sessions, participants will interface with a custom-built force-field able to exert mediolateral forces on the legs, which will be in "error augmentation" mode. This training period will be followed by a 12-week follow-up period. Five assessment sessions will be interspersed throughout this total 24-week period.

Behavioral: Error augmentation

Activity matched control

SHAM COMPARATOR

Participants will complete a 12-week training program, in which they practice walking on a treadmill for 30-minutes during twice-weekly training sessions. During these sessions, participants will interface with a custom-built force-field able to exert mediolateral forces on the legs, which will be in "transparent" mode. This training period will be followed by a 12-week follow-up period. Five assessment sessions will be interspersed throughout this total 24-week period.

Behavioral: Activity matched control

Interventions

Error reductionBEHAVIORAL

During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs toward mechanically-appropriate mediolateral locations, having the effect of reducing the errors in foot placement that are often present among individuals who have experienced a stroke.

Error reduction

During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs away from mechanically-appropriate mediolateral locations, having the effect of amplifying the errors in foot placement that are often present among individuals who have experienced a stroke.

Error augmentation

During training sessions, participants will interface with a custom-built force-field while they walk. The force-field will essentially get out of the way, producing minimal forces on the legs, and having no direct effect on the errors in foot placement that are often present among individuals who have experienced a stroke.

Activity matched control

Eligibility Criteria

Age21 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • At least 21 years old
  • Experience of a stroke 6 months prior to participation
  • Preferred overground gait speed of at least 0.2 m/s
  • Ability to walk at self-selected speed for 3 minutes without a cane or walker
  • Provision of informed consent.

You may not qualify if:

  • Resting heart rate above 110 beats/min
  • Resting blood pressure higher than 200/110 mm Hg
  • History of congestive heart failure, unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during activities of daily living
  • Preexisting neurological disorders or dementia
  • History of major head trauma
  • Legal blindness or severe visual impairment
  • Life expectancy \<1 yr; 8)
  • History of deep vein thrombosis or pulmonary embolism within 6 months
  • Uncontrolled diabetes with recent weight loss, diabetic coma, or frequent insulin reactions
  • Orthopedic injuries or conditions (e.g. joint replacements) in the lower extremities with the potential to alter the gait pattern.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ralph H. Johnson VA Medical Center, Charleston, SC

Charleston, South Carolina, 29401-5799, United States

Location

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Limitations and Caveats

The overall dropout rate of this study was increased by the research shutdown with the coronavirus pandemic.

Results Point of Contact

Title
Jesse Dean
Organization
Ralph H. Johnson VAMC / MUSC

Study Officials

  • Jesse C. Dean, PhD

    Ralph H. Johnson VA Medical Center, Charleston, SC

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
FED
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 4, 2016

First Posted

November 15, 2016

Study Start

April 1, 2017

Primary Completion

March 31, 2020

Study Completion

March 31, 2020

Last Updated

June 3, 2024

Results First Posted

July 28, 2021

Record last verified: 2023-12

Data Sharing

IPD Sharing
Will share

De-identified, anonymized data sets will be available to other investigators or members of the public upon request. These data sets will be made available upon completion of data collection, processing, and initial statistical analyses. The data sets will include physiological measures related to functional mobility, as well as the results of clinical tests.

Locations